Lavior Pharma Inc.

Lavior Pharma Inc. manufactures botanical-based wound care and skin barrier products backed by 16 years of research. The company specializes in formulations derived from the Inula viscosa AGS-RIED plant species, combining botanical ingredients with clinical science for diabetic and general wound care applications. Primary product lines include hydrogel wound dressings, diabetic wound therapy gels, post-surgical skin barrier gels, and diabetic skin barrier creams in 1oz and 3.4oz formats. Products are formulated to support skin health, facilitate moist wound healing, and address diabetic skin complications including ulcer prevention and callus management. The company has achieved media visibility through coverage on ABC News, NBC News, CBS News, Fox News, and The CW. Lavior markets its products directly to consumers through e-commerce channels and positions formulations as alternatives to traditional ointments for both clinical and home care settings. The company maintains educational content addressing diabetic skin care, wound dressing techniques, continuous glucose monitor site healing, and footwear-related ulcer prevention. While specific FDA or ISO certifications are not explicitly detailed on the website, the emphasis on clinically backed formulations and 16 years of research development suggests regulatory compliance. Distribution and service capabilities appear focused on direct-to-consumer channels with newsletter and VIP club engagement models.